BIOMAT Database Logo BIOMAT Database Logo

Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab. 2016

Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003879 Dermatologic Agents Drugs used to treat or prevent skin disorders or for the routine care of skin. Agent, Dermatologic,Agent, Dermatological,Agents, Dermatologic,Dermatologic Agent,Dermatological Agents,Agents, Dermatological,Dermatological Agent
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis.
September 2023, International journal of rheumatic diseases,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab-Induced Bullous Pemphigoid in a Patient With Psoriatic Arthritis.
June 2023, American journal of therapeutics,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Thrombocytopenia possibly induced by etretinate in a psoriatic patient.
November 2005, The Journal of dermatology,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab-induced systemic lupus erythematosus in psoriatic arthritis.
January 2023, ARP rheumatology,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab.
August 2018, Clinical and experimental dermatology,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab: A Review in Psoriatic Arthritis.
March 2021, Drugs,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab: A Review in Psoriatic Arthritis.
July 2016, Drugs,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab and psoriatic arthritis.
March 2017, Prescrire international,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Secukinumab Use in Psoriatic Arthritis.
December 2018, The Journal of the Association of Physicians of India,
Takaya Komori, and Atsushi Otsuka, and Yuki Honda, and Shuto Kanameishi, and Tetsuya Honda, and Kenji Kabashima
Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
June 2008, Journal of clinical pharmacy and therapeutics,
Copied contents to your clipboard!